ENElisabeth E. Nibbelke

Elisabeth E. Nibbelke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisabeth E. Nibbelke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

    by On Behalf Of The Dutch Rsv Neonatal Network, Maarten O. Blanken, Geert W. Frederix, Wendy J. Ungar, Elisabeth E. Nibbelke, Hendrik Koffijberg, Elisabeth A. M. Sanders, Maroeska M. Rovers, Louis Bont

    The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.


  • Open Access

    Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

    by On Behalf Of The Dutch Rsv Neonatal Network, Maarten O. Blanken, Geert W. Frederix, Elisabeth E. Nibbelke, Hendrik Koffijberg, Elisabeth A. M. Sanders, Maroeska M. Rovers, Louis Bont

    The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving.Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.